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Background: Antimicrobial lock therapy (ALT) may be considered as adjunctive therapy in 
the treatment of catheter-related bloodstream infections (CRBSI) when catheter removal is not 
a favorable option.
Objective: To evaluate the outcomes associated with ALT as adjunctive treatment of 
CRBSI.
Methods: This was a 24-month retrospective case series analysis evaluating patients treated for 
more than 24 hours with ALT. The primary outcome was blood culture sterilization for 30 days 
posttherapy. The impact of ALT duration and time to initiation on central venous catheter (CVC) 
salvage were evaluated. Logistic regression modeled the association between ALT and steriliza-
tion rates, with a prespecified level of significance (α) of 0.1.
Results: Twenty-six cases were included in data analysis. Patients included ranged from 
5 months to 82 years of age; 77% of patients were receiving total parenteral nutrition or chemo-
therapy. The majority of patients received vancomycin, daptomycin, or gentamicin combined 
with heparin in a lock solution. Blood culture sterilization was achieved in 69.2% of cases, and 
sterilization plus CVC retention was achieved in 11 cases (42.3%). Longer durations of ALT 
($9 days) were significantly correlated with blood culture sterilization (odds ratio = 1.367, 
P = 0.077).
Conclusion: ALT used as an adjunct to systemic therapy for adequate duration in CRBSI can 
achieve CVC sterilization and retainment without subsequent infectious complications.
Keywords: antimicrobial lock therapy, central venous catheter, bacteremia, central line-
associated bloodstream infection
Introduction
Catheter-related bloodstream infections (CRBSI) are a primary concern in patients 
with long-term tunneled catheters, occurring in approximately 5% of the over 5   million 
central venous catheters (CVC) inserted annually.1,2 Significant morbidity and   mortality 
may result with rates as high as 25% in high-risk patients with   long-term CVC for 
hemodialysis, intravenous chemotherapy, and total parenteral nutrition (TPN).2 
Gram-positive cocci are the most prevalent pathogens responsible for up to 70% of 
CRBSI, most commonly Staphylococcus aureus and coagulase-negative   Staphylococci 
(CoNS).3 Removal of the catheter remains the primary intervention due to the   formation 
of intraluminal biofilm.
Salvage therapy has been used, primarily in patients where catheter removal is not a 
viable option. This may be achieved by the instillation of a highly concentrated antimi-
crobial containing solution into the catheter lumen, otherwise known as antimicrobial Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
124
Bookstaver et al
lock therapy (ALT). Concentrations of 100–1,000 times the 
minimum inhibitory concentration (MIC90) of the planktonic 
bacteria may be required to achieve bioactivity against 
  sessile bacteria within a biofilm.4 ALT is recommended by 
the   Infectious Diseases Society of America (IDSA) Guide-
lines for management of CRBSI as an adjunct therapy to 
systemic antibiotics when the catheter is retained.1 A recent 
report from the Emerging Infections Network (EIN) of the 
IDSA demonstrated that approximately 37% of respondents 
use ALT in a treatment modality for catheter salvage.5 The 
overwhelming majority of clinicians (75%–86%) use van-
comycin as their antibiotic of choice for CRBSI secondary 
to gram-positive pathogens.5 Published data on clinical out-
comes in a treatment modality, as opposed to prophylactic 
use of ALT, is limited. Combined with systemic antibiotics, 
ALT has been shown to produce a clinical cure and result in 
catheter salvage in nearly 40%–100% of patients.6–9 Overall, 
better clinical outcomes are observed in CRBSI secondary 
to CoNS and gram-negative bacilli.1,6–9
This case series analysis details experience with 
  antimicrobial-anticoagulant solutions used as adjunctive 
therapy to systemic antibiotics in the treatment of CRBSI in 
patients with long-term CVC for hemodialysis, chemotherapy, 
and TPN. Included in this analysis are antimicrobial lock solu-
tions with no previously reported clinical outcomes data.
Patients and methods
This was a retrospective case series analysis conducted at 
a single, university teaching hospital. Institutional review 
board approval was granted prior to data collection and 
presentation. Patients who received ALT over a 30-month 
period from May 2005 to November 2007 were screened for 
study inclusion. Cases were included if the patient received 
ALT for more than 24 hours in a treatment modality of an 
established CRBSI. Diagnosis of a CRBSI was based on clini-
cal and microbiological evidence as defined by the National 
Patient Safety Network and Centers for Disease Control and 
Prevention and monitored by the institution’s infection control 
staff.3 Cases were excluded if the patient had negative blood 
cultures before beginning ALT or if ALT was used less than 
24 hours. In patients who received multiple courses of ALT, 
each course was documented as a separate case if it was 
deemed a new CRBSI. Infections were defined as a relapse 
if positive cultures from the CVC and/or peripheral blood 
resulted in the same organism within 30 days of treatment.
At this institution, nurses administering the ALT are 
instructed to maintain a locked lumen whenever the CVC is not 
in use; additional syringes of the lock solution are supplied by 
pharmacy upon request. In cases of dual-lumen CVC, a single 
lumen is locked for 24 hours continuously, whereas the other 
lumen is used for patient access. This process is alternated every 
other day. In patients receiving hemodialysis through a CVC, 
lumens are locked between dialysis sessions, for up to 72 hours 
continuously. Nurses routinely flush the lock solutions, unless 
the patient is not receiving the same agent systemically; the 
nurses are instructed to aspirate the solution in these cases.
The primary objective was to assess the percent of sterilized 
blood cultures from treatment with ALT. Primary endpoints 
were defined as negative blood cultures from both peripheral 
and CVC draws for the identified CRBSI pathogen for 30 days 
after end of ALT and systemic therapy. The secondary endpoints 
were CVC retention, infectious sequelae, and resolution of 
clinical signs and symptoms of infection. Host, patient, and 
treatment factors (eg, duration of ALT, concurrent systemic 
antibiotics, time to initiation of ALT, antibiotic used in ALT 
solution, causative organism) were examined for association 
with success of ALT. Performance of specific antimicrobial lock 
solutions and pathogen-specific outcomes were also analyzed. 
Data were collected to include age, gender, weight,   indication 
for CVC, concurrent systemic antibiotic therapy, white blood 
cell (WBC) count, C-reactive protein (CRP),   temperature curve, 
and all culture and susceptibility data during and for 30 days after 
conclusion of antibiotic lock and systemic antibiotic therapy 
for the defined CRBSI. All data regarding the lock solutions 
were collected to include concentrations of antimicrobials and 
anticoagulants, duration, and dwell time.
The data analysis used the most recent version of SAS 
(SAS Institute Inc, Cary, NC, USA). A multivariate logistic 
regression modeled the association between ALT and steril-
ization rates by estimating the odds ratio (OR). Significance 
was determined by the P-value of the associated Wald test 
compared with a 0.10 level of significance. The level of sig-
nificance (α) was chosen to be 0.10 due to the small sample 
size. An OR greater than 1 indicates increased risk or positive 
association, whereas OR less than 1 indicates decreased risk 
or negative association. The following control/confounding 
variables were initially included in the model, but eventually 
dropped due to insignificance: age, weight, gender, reasons 
for CVC, pathogen, and specific lock solution received. 
Descriptive statistics were used to further define primary 
and secondary endpoint data.
Results
Over the 30-month study period, a total of 29 cases of ALT 
for CRBSI treatment were identified. Twenty-six cases were 
included in data analysis from 15 unique patients. One case Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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was excluded because ALT was used for less than 24 hours, 
and 2 cases were excluded because the patients had nega-
tive blood cultures before beginning ALT. Patients included 
ranged from 5 months to 82 years of age. The breakdown 
for CVC placement in the 26 cases was as follows: TPN 
(57.7%, n = 15), intravenous chemotherapy (Dnc; 23.1%, 
n = 6), hemodialysis (HD; 15.4%, n = 4), and other long-term 
parenteral access (3.8%, n = 1). The majority of cases (62%) 
were pediatric patients less than 18 years of age. One patient 
(case #23, Table 1) was neutropenic (WBC , 500 cells/mm3) 
at the initiation of ALT. No patients carried a diagnosis of 
HIV/AIDS. Table 1 provides a complete case analysis.
Antimicrobials used in lock solutions included 5 mg/mL 
or 10 mg/mL of vancomycin (n = 8), 1 mg/mL of daptomycin 
(n = 6), 2.5 mg/mL or 5 mg/mL of gentamicin (n = 6), and 
70% ethanol (n = 1). In 5 cases, combinations of antimicrobial 
agents were used in lock solutions: vancomycin plus gentami-
cin (n = 3) and vancomycin plus ethanol (n = 2). The majority 
of lock solutions (24/26) were combined with heparin at 
variable concentrations (10 units/mL up to 5,000 units/mL) 
depending on the indication for the CVC. Ethanol was not 
mixed with an anticoagulant in solution due to compatibility 
concerns. One patient received 5 mg/mL of vancomycin 
alone in solution without the addition of heparin (case #18, 
Table 1). In the 2 patients receiving vancomycin plus ethanol 
locks, the agents were not combined in solution, rather the 
lumens were locked on alternating days with each individual 
antimicrobial in solution. No alternative anticoagulants were 
used in any of the lock solutions.
Concurrent systemic antibiotics were given in all cases, 
with the exception of 1 patient with an α-hemolytic strep-
tococcal infection, who received daptomycin lock therapy 
alone. In most cases (22/26), the choice of agents for local 
lock therapy matched an agent in their concurrent systemic 
regimen. In the other 4 cases, 1 patient was receiving no 
systemic therapy, 1 patient was receiving an ethanol lock, and 
the other 2 patients were receiving gentamicin plus heparin 
lock therapy, while receiving alternative systemic β-lactams. 
In each case, the patient was receiving at least 1 active agent 
based on automated susceptibility profiles. The majority of 
causative organisms were gram-positive, with staphylococcal 
species being the most predominant. Of the 26 cases, 34.6% 
were CoNS, 19.2% methicillin-resistant S. aureus (MRSA), 
23.1% gram-negative bacilli, 7.6% Enterococcus species, 
3.8% Streptococcus species, and 11.5% polymicrobial.
The primary end point of blood culture and CVC ster-
ilization at 30 days after conclusion of systemic antibiotic 
therapy was achieved in 69.2% (n = 18) of cases. Daptomycin 
and gentamicin achieved catheter sterilization in 100% of 
cases. When used as the sole antibiotic in solution (n = 8), 
vancomycin achieved a sterilization rate of 37.5%. In all 
cases where daptomycin or vancomycin was used in a lock 
solution, these agents were also given as concurrent systemic 
therapy. Overall, culture sterilization rates in CRBSI caused 
by gram-positive pathogens were 80% for S. aureus, all of 
which were MRSA, and 77.7% for CoNS. One case of a 
polymicrobial infection secondary to CoNS and S. aureus 
resulted in sterilization failure and removal of the CVC. 
CRBSI secondary to gram-negative pathogens were steril-
ized at a rate of 83.3%. A total of 13 CVC cases (50%) were 
salvaged with ABL therapy. In these 13 cases with CVC 
retainment, 1 patient experienced a recurrent CoNS bacter-
emia 2 months after the end of therapy (case #20, Table 1). 
The patient ultimately expired; however, it was most likely 
attributed to progressive non-Hodgkin’s lymphoma. Two of 
the CVC were retained despite persistent positive cultures in 
patients requiring continued hemodialysis. Eleven patients 
(42.3%) achieved both blood culture sterilization and CVC 
salvage.
At the time of this case series analysis, the ALT dwell 
time was not documented at the institution; however, based 
on drug utilization records, the estimated mean dwell time 
in nonhemodialysis patients was 14 hours daily. In the 
cases of multilumen CVC, both lumens were locked with 
antimicrobial solution. Patients with a CVC in place for 
hemodialysis access received continuous dwells between 
sessions. The mean duration of ALT was 8.9 days. Longer 
ALT duration was significantly correlated with achieving 
catheter sterilization with an OR of 1.367 for each day 
above mean (P = 0.077). Of 10 patients who received at least 
10 days of ALT, 9 (90%) achieved the primary endpoint of 
sterilization. In respect to ALT initiation, 50% (n = 13) of 
lock solutions were initiated within 48 hours of suspected 
CVC infection or initiation of systemic antimicrobials. 
Successful sterilization was achieved in 77% of these cases, 
although there was no significant correlation with day of ALT 
initiation (OR = 1.034, P . 0.1). There was no difference in 
outcomes based on number of lumens (single vs double) or 
type of catheter in place. No other host, pathogen, or treat-
ment factors were significantly associated with increased 
sterilization rates.
Clinically, patients experienced defervescence an aver-
age of 42 hours after ALT initiation. In 1 case, the subject 
spiked a fever on day 10 of ALT and the CVC was sub-
sequently removed. Data regarding WBC count and CRP 
were not reported due to inconsistent laboratory obtainment Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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of these markers. One patient expired during the study 
period while receiving ALT. The catheter was retained; 
however, the death was determined unrelated to infectious 
complications.
Discussion
The use of long-term CVC is associated with a substantial risk 
of bloodstream infections. Although CVC removal is optimal, 
it is not always feasible in many patients who may have limited 
vascular access or high-risk surgical candidates. In our study, 
nearly 70% of patients successfully sterilized their blood with 
local ALT combined with systemic antibiotics, consistent with 
previous results. CVC removal was prevented in a total of 
13 cases, and 11 of these patients had sustained negative cul-
tures for the causative pathogen during the 30-day post-ALT 
period. Few randomized studies have been conducted inves-
tigating ALT in a treatment modality. Available data exists 
primarily from retrospective reports, open-label prospective 
studies, and case reports. Rjinders et al9 found that patients 
treated with ALT plus systemic therapy achieved a 67% cure 
rate compared with 43% cure rate in patients receiving only 
systemic antibiotics. Patients received either vancomycin 
or ceftazidime at a concentration of 500 mg/L plus heparin 
depending on the causative organism. Fortun et al10 reported 
similar results (84% success rate) in a retrospective analysis of 
29 episodes treated with ALT plus systemic antibiotics. Anti-
biotics used in that study included vancomycin, ciprofloxacin, 
or gentamicin lock solutions at 2 mg/mL plus heparin resulting 
in an 84% clinical and microbiological success rates.10 Addi-
tional studies have also produced similar rates of clinical and 
microbiological cure, including immunocompromised patients 
with neutropenia.11–14
In our study, duration of ALT was associated with a 
significant (P = 0.077) increased chance of success. Each 
additional day of therapy beyond 9 days (mean = 8.9 days) 
of therapy resulted in a 1.367 times increased odds. IDSA 
guidelines for management of CRBSI suggest a targeted 
duration of 14 days. In a 2007 IDSA EIN antibiotic lock 
utilization report, 70% of respondents target 10–14 days 
for duration.5 Many prospective studies with successful 
outcomes used 14–21 days of ALT.6,7,9,11 A single study did 
demonstrate an 86% success rate against CRBSI primarily 
due to CoNS in an oncology population with only 3 days 
of ALT.13 Shorter durations, however, have been associ-
ated with treatment failures and attributable mortality 
from CRBSI.10 Onder et al15 demonstrated a significant 
improvement in treatment outcomes in pediatric patients 
on chronic hemodialysis when ALT was initiated early Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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(,72 hours after suspected infection) vs late in the course 
of infection.15 In our study, ALT was initiated on average on 
day 3 of suspected CRBSI. There was no correlation to ALT 
success and day of initiation; however, a 77% sterilization 
rate resulted in patients when ALT was initiated #48 hours 
into systemic therapy. Each of the 3 patients who received 
ALT on day 1 achieved sterilization and successful cath-
eter salvage. Delay in consultation of infectious diseases 
pharmacists and physicians regarding the use of ALT and 
the inability to continue lock therapy following hospital 
discharge likely contribute to delayed initiation, shortened 
duration, and ultimately lower success rate. The available 
data supports the early initiation of ALT and continuation 
for a minimum of 14 days or for the complete duration of 
systemic therapy.
Vancomycin is the most studied antibiotic in both a 
treatment and prophylactic modality.6–12,16 In our case series, 
vancomycin was only successful in 37.5% of cases when 
used as the only antibiotic in solution. Vancomycin was 
also used in combination locks with both ethanol (vanco-
mycin and ethanol locked separately on alternating days) 
and gentamicin (combined in solution) in 5 cases, with 2 
reported failures. In vitro reports have suggested that vanco-
mycin demonstrates less activity against biofilm-producing 
organisms and in a catheter model of infection compared 
with other agents, including minocycline, rifampin, and 
ciprofloxacin.17,18 An additional study demonstrated a more 
rapid elimination of S. epidermidis biofilms with gentami-
cin, linezolid, and eperezolid compared with 10 mg/mL 
of vancomycin.19 This lack of activity may be related to 
the delayed penetration of vancomycin into biofilm and 
decreased activity in the biofilm environment despite con-
centrations up to 1,000 times MIC90 values of planktonic 
bacteria.18 Systemic vancomycin was used concurrently in 
all cases where vancomycin was used in lock solution in 
our study. The average duration of vancomycin ALT was 
9.12 days and lock therapy was initiated, on an average of 
day 3 of suspected CRBSI; no correlation to failure was 
noted. Although variable concentrations were used in this 
study, 5 mg/mL and 10 mg/mL, there should be limited 
difference in treatment outcomes given the concentrations 
relative to MIC of the planktonic bacteria (at least 500 times 
the MIC). One major influence on the lack of comparable 
success of vancomycin ALT is 50% of CRBSI were sec-
ondary to MRSA and enterococcal species, both known to 
have heightened virulence and lower eradication rates when 
treating biofilm-producing organisms compared with other 
pathogens, including CoNS.20–22
In this case series, lock solutions containing the single 
agents, daptomycin or gentamicin, achieved 100% success 
in blood culture sterilization. Gentamicin locks were used 
only against gram-negative pathogens in our study, including 
1 polymicrobial infection. Of note, success was achieved in 
both cases of multidrug-resistant Acinetobacter baumannii. 
Daptomycin was successfully used in 6 cases, 4 of which 
were CoNS and 1 case of MRSA. Daptomycin concentra-
tions of 1 mg/mL were used at this institution. Addition of 
lactated Ringer’s solution for calcium supplementation to 
reconstituted daptomycin is required for bioactivity.23 In vitro 
reports against biofilm-producing pathogens and data in a 
prophylactic modality support the utilization of both dap-
tomycin and gentamicin in lock solutions.6,10,22–24 Ethanol as 
a 70% solution was also used in 3 cases in our study, twice 
in combination with vancomycin (vancomycin and ethanol 
locked separately on alternating days). The 1 pediatric patient 
who received daily ethanol locks did achieve success in this 
polymicrobial (Klebsiella pneumoniae plus Enterobacter 
aerogenes) CRBSI. When used on alternating days with 
vancomycin, ethanol locks achieved a 50% (1/2) success rate. 
The failure was a CRBSI secondary to MRSA in a pediatric 
patient. Ethanol (70%) has demonstrated success, 67%–80%, 
in additional prospective studies with limited number of 
patients.10,25 This high success rate was noted despite limited 
dwell times (4 hours/day) and shorter duration of therapy (5 
days) in 1 study.10 A complete review of available literature 
regarding ethanol lock therapy has been recently published.26 
Additional antimicrobials in lock solutions, including cefazo-
lin, ceftazidime, and minocycline among others not included 
in our case series, have been investigated and may be viable 
options against targeted pathogens.1,9–11 Alternatives to hepa-
rin as an anticoagulant in solution, such as EDTA and citrate, 
have been used in combination with gentamicin, minocycline, 
and tigecycline.17,18,23,24,27–29 Given the effects of these metal 
ion chelators on biofilm integrity and synergism with other 
antimicrobials, they should be considered for use in lock 
therapy.17,18,30,31 These alternatives may also be viable options 
in patients unable to tolerate heparin in solution.
Our analysis was designed to describe clinical outcomes 
for several antimicrobial solutions against commonly encoun-
tered pathogens responsible for CRBSI. Inherent limitations 
for further analysis include the heterogeneous population, 
lack of consistency between responsible pathogens and 
treatment with specific lock solutions, variable concurrent 
systemic therapy, and inclusion of both pediatric and adult 
patients with variable indications for CVC. Because the 
administration and process of ALT was uniform, we were Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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able to appropriately analyze the influence of specific host 
and technique factors, such as duration and time of ALT 
initiation. Although varied concentrations of antimicrobials 
were used in some cases (eg, vancomycin and gentamicin), 
each concentration remained at least 50 times the MIC of the 
planktonic bacteria and was typically in the 100–1,000 times 
range. Given these concentrations, we feel there would be 
little influence on the clinical outcomes between variable con-
centrations. Due to the small treatment population, no direct 
analysis was conducted between antimicrobial lock solutions. 
Our inability to accurately detect prolonged catheter survival 
did not allow us to report the number of catheter days saved. 
In addition, we were unable to report exact dwell times of the 
lock solutions; however, medication administration records 
were used to ensure lock solutions were allowed to dwell 
when the CVC was not in use and provide estimated times. 
Heparin was used as the anticoagulant in all lock solutions 
in our study, thus we were unable to report any results with 
antimicrobials alone or solutions containing alternative 
anticoagulants.
Conclusion
Patients who received ALT in combination with active 
systemic therapy for adequate duration achieved steriliza-
tion of blood and CVC cultures despite CVC retainment. 
Those who successfully retain the CVC should be care-
fully monitored for resolution of infection and develop-
ment of infectious complications. In this study, 1 patient 
had a subsequent episode of bacteremia 2 months after 
conclusion of initial therapy, but no other sequelae were 
identified. CRBSI secondary to enterococcal species and 
S. aureus resulted in a higher failure rate, and careful 
risk-benefit should be weighed before initiating ALT in 
these patients. Given the lack of success with vancomycin 
ALT and previous data acknowledging limited effects on 
biofilm cells, it should be used with caution. In contrast 
to vancomycin, daptomycin and gentamicin lock solutions 
resulted in 100% success in achieving sterilization of blood 
and CVC. Selection of antimicrobial and anticoagulants 
in lock solutions should be made on bioactivity and clini-
cal data against biofilm cells, available compatibility and 
stability information, and targeted at the likely pathogens 
responsible for CRBSI. Although CVC removal remains 
the treatment of choice, early initiation of ALT upon 
suspicion of CRBSI combined with protracted use for at 
least 2 weeks will increase the likelihood of successful 
treatment outcomes and should be considered a reasonable 
therapeutic alternative.
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